{"abstract": "The drug maker Mylan, which rejected one offer and was itself rebuffed on another, may be overpaying for the Swedish company Meda.", "web_url": "https://www.nytimes.com/2016/02/12/business/dealbook/mylans-new-deal-may-not-be-the-one-shareholders-wanted.html", "snippet": "The drug maker Mylan, which rejected one offer and was itself rebuffed on another, may be overpaying for the Swedish company Meda.", "lead_paragraph": "Mylan, the generic and specialty drug company, finally has a deal \u2014 but probably not the one its shareholders would have preferred. Three months after its rival Perrigo refused its hostile $26 billion offer, Mylan agreed to buy Sweden\u2019s Meda for $7.2 billion.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Mylan\u2019s New Deal May Not Be the One Shareholders Wanted", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Mylan Inc", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Meda AB", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Perrigo Company", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Teva Pharmaceutical Industries Ltd", "rank": 5, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 6, "major": "N"}], "pub_date": "2016-02-11T19:28:54+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/b18579ef-047c-5d4d-89d2-ef56bc96ff1a", "word_count": 343, "uri": "nyt://article/b18579ef-047c-5d4d-89d2-ef56bc96ff1a"}